CRIS Current Research Information System

PICCALUGA, PIER PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.566
EU - Europa 13.325
AS - Asia 11.912
SA - Sud America 794
AF - Africa 757
Continente sconosciuto - Info sul continente non disponibili 682
OC - Oceania 23
Totale 43.059
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.303
IT - Italia 4.722
CN - Cina 3.425
SG - Singapore 3.293
GB - Regno Unito 2.695
VN - Vietnam 2.604
DE - Germania 1.276
SE - Svezia 1.223
FR - Francia 738
HK - Hong Kong 737
IN - India 661
UA - Ucraina 575
BR - Brasile 572
RU - Federazione Russa 569
IE - Irlanda 372
ZA - Sudafrica 280
NL - Olanda 258
JP - Giappone 223
EE - Estonia 174
TG - Togo 170
KR - Corea 166
CH - Svizzera 158
BD - Bangladesh 154
CA - Canada 154
CI - Costa d'Avorio 143
FI - Finlandia 142
AR - Argentina 86
IR - Iran 82
JO - Giordania 77
ID - Indonesia 71
PH - Filippine 64
TR - Turchia 64
BG - Bulgaria 63
BE - Belgio 59
SC - Seychelles 48
TH - Thailandia 46
IQ - Iraq 44
GR - Grecia 41
PL - Polonia 40
EC - Ecuador 39
MX - Messico 39
PK - Pakistan 37
ES - Italia 34
NG - Nigeria 28
TW - Taiwan 28
CL - Cile 27
HR - Croazia 27
LU - Lussemburgo 25
AT - Austria 24
CO - Colombia 24
RO - Romania 24
LB - Libano 22
SA - Arabia Saudita 22
UZ - Uzbekistan 22
PY - Paraguay 18
KE - Kenya 15
LT - Lituania 15
AU - Australia 13
EG - Egitto 13
JM - Giamaica 12
MY - Malesia 12
MA - Marocco 11
PT - Portogallo 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 10
VE - Venezuela 10
ET - Etiopia 9
UY - Uruguay 9
AL - Albania 8
CZ - Repubblica Ceca 8
DZ - Algeria 8
HU - Ungheria 8
IL - Israele 8
NZ - Nuova Zelanda 8
SK - Slovacchia (Repubblica Slovacca) 8
KZ - Kazakistan 7
NP - Nepal 7
PE - Perù 7
GT - Guatemala 6
NI - Nicaragua 6
DO - Repubblica Dominicana 5
GH - Ghana 5
HN - Honduras 5
PR - Porto Rico 5
RS - Serbia 5
KG - Kirghizistan 4
MD - Moldavia 4
OM - Oman 4
PA - Panama 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BS - Bahamas 3
GP - Guadalupe 3
IS - Islanda 3
A2 - ???statistics.table.value.countryCode.A2??? 2
Totale 42.335
Salva come PNG Salva come JPEG
Città #
Southend 2.359
Singapore 2.229
Fairfield 1.583
Ashburn 1.544
Chandler 930
San Jose 813
Houston 800
Woodbridge 759
Seattle 718
Wilmington 704
Hong Kong 695
Cambridge 576
Princeton 576
Ann Arbor 519
Ho Chi Minh City 519
Santa Clara 493
Hanoi 454
Dong Ket 450
Beijing 447
Milan 428
Dublin 363
Rome 343
Hefei 340
Council Bluffs 319
Bologna 316
Boardman 315
Jacksonville 299
Lauterbourg 279
Nanjing 271
Padova 254
Westminster 241
Los Angeles 214
New York 200
Tokyo 193
Lomé 169
Abidjan 143
Jinan 137
Shenyang 135
Berlin 131
Naples 131
Saint Petersburg 127
Seoul 124
Turin 124
Buffalo 121
Helsinki 119
Bern 118
Bremen 110
Hebei 107
Dallas 100
Changsha 94
Nanchang 88
Florence 87
São Paulo 84
San Diego 83
Mülheim 82
Frankfurt am Main 80
Redondo Beach 78
Amman 76
Guangzhou 76
Da Nang 72
Tianjin 71
Parma 69
Haiphong 63
Phoenix 62
Shanghai 61
Sofia 61
Medford 60
Hangzhou 58
Jiaxing 56
Brussels 54
Chicago 52
Verona 52
Hyderabad 49
Zhengzhou 49
Toronto 46
London 45
Montreal 43
Haikou 42
Falls Church 41
Bengaluru 40
Redwood City 40
Orem 39
Palermo 39
Munich 38
Taizhou 38
San Francisco 36
Dearborn 35
Ningbo 35
Taiyuan 35
Yubileyny 35
The Dalles 34
Johannesburg 33
Mahé 33
Jakarta 32
San Venanzo 32
Cagliari 31
Norwalk 29
Olalla 29
Bari 28
Warsaw 28
Totale 26.092
Salva come PNG Salva come JPEG
Nome #
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 1.939
Instillazione diretta intranasale di amfotericina B liposomiale nella terapia delle micosi nasali. 887
Linfomi non Hodgkin di derivazione dai linfociti T-periferici. 676
Leucemia Acuta Linfoide. 540
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 358
ANALYSIS OF THE CODING GENOME OF SPLENIC MARGINAL ZONE LYMPHOMA REVEALS MUTATIONAL ACTIVATION OF NOTCH2 AND OTHER PATHWAYS REGULATING MARGINAL ZONE DIFFERENTIATION 331
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 288
Biology and treatment of follicular lymphoma. 285
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia 270
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 261
Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified 256
CDKN1B/p27 expression in peripheral T cell lymphoma not otherwise specified. 254
The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies 246
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance 239
IFI16 expression is related to selected transcription factors during B-cell differentiation 232
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification? 230
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma 227
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. 225
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. 221
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. 220
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcome 220
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation 219
Advances in the treatment for haematological malignancies. 217
Linfomi non Hodgkin di derivazione dai linfociti T-periferici primitivi della cute. 217
Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation 216
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 214
Expression of CD52 in peripheral T-cell lymphoma. 211
Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. 210
Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. 210
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response? 209
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation. 209
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas 208
Conditioning regimens in acute myeloid leukemia. 208
FIRMA MOLECOLARE E SUOI USI COME AGENTE DIAGNOSTICO 204
Epstein-Barr Virus-Induced Metabolic Rearrangements in Human B-Cell Lymphomas 201
MINIMAL RESIDUAL DISEASE (MRD) EVALUATION IN LYMPHOMAS WITHIN THE FIL (FONDAZIONE ITALIANA LINFOMI) MRD NETWORK: INTER-LABORATORY REPRODUCIBILITY ON BORDERLINE SAMPLES 200
Systemic Epstein-Barr-virus-positive T cell lymphoproliferative childhood disease in a 22-year-old Caucasian man: A case report and review of the literature 200
Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study 197
Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition 197
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 197
Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome 196
Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy 196
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 196
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 194
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma 194
Pathobiologic Roles of Epstein-Barr Virus-Encoded MicroRNAs in Human Lymphomas 194
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 193
Unveiling another missing piece in EBV-driven lymphomagenesis: EBV-encoded microRNAs expression in EBER-negative Burkitt lymphoma cases 192
Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway. 192
Single-Step IGHV Next-Generation Sequencing Detects Clonality and Somatic Hypermutation in Lymphoid Malignancies: A Phase III Diagnostic Accuracy Study 191
Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas 191
Duplex real-time polymerase chain reaction assay for the detection of human KIPyV and WUPyV in nasopharyngeal aspirate pediatric samples 190
Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma 189
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 188
Frequent Elevation of Akt Kinase Phosphorylation in Blood Marrow and Peripheral Blood Mononuclear Cells from High Risk myelodysplastic Syndrome Patients 187
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 187
CDKN1B/P27 expression in peripheral T-cell lymphoma not otherwise specified 187
A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma. 187
Molecular signature of Epstein Barr virus-positive Burkitt lymphoma and post-transplant lymphoproliferative disorder suggest different roles for Epstein Barr virus 187
Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma 186
Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis 184
Pathobiology of hodgkin lymphoma. 183
Assessment Of Sars-Cov-2 Igg And Igm Antibody Detection With A Lateral Flow Immunoassay Test 182
BCL10 down-regulation in peripheral T-cell lymphomas. 180
Prompt resolution of nasal aspergillosis with intranasal instillation of liposomal amphotericin-B (amBisome) and granulocyte transfusions 178
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab. 178
SNPs Array Karyotyping in Non-Hodgkin Lymphoma 178
Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. 177
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma 176
Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi 176
Linfomi a cellule T periferiche NAS: nuovo indice prognostico. 175
Characterization of a new monoclonal antibody against PAX5/BASP in 1525 paraffin-embedded human and animal tissue samples. 174
Clonality analysis of immunoglobulin gene rearrangement by next-generation sequencing in endemic burkitt lymphoma suggests antigen drive activation of bcr as opposed to sporadic burkitt lymphoma 174
Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia 174
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 173
Molecular profiling of aggressive lymphomas 173
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 173
Primary cardiac non-Hodgkin lymphoma presenting with atrial flutter and pericardial effusion. 172
Chronic inflammation, including Autoimmunity, and Lymphomagenesis. 172
Pathobiology of anaplastic large cell lymphoma. 171
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups 171
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 171
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 170
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. 170
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 168
Molecular genetics of peripheral T-cell lymphomas 168
The cell of origin of Burkitt lymphoma: germinal centre or not germinal centre? 168
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 168
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 167
The development of more than one histologic type of lymphoma in the same patient is frequent and confers a worse prognosis 164
Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients 163
The presence of Epstein-Barr virus significantly impacts the transcriptional profile in immunodeficiency-associated Burkitt lymphoma 163
Preferential usage of specific immunoglobulin heavy chain variable region genes with unmutated profile and advanced stage at presentation are common features in patients with chronic lymphocytic leukemia from Senegal 163
Targeted molecular therapy in peripheral T-cell lymphomas 162
Vascular endothelial growth factor A (VEGFA) expression in mycosis fungoides 162
Pathobiology of ALK-negative anaplastic large cell lymphoma. 161
The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. 161
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients 159
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML 159
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma 156
Totale 22.983
Salva come PNG Salva come JPEG
Categoria #
all - tutte 114.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 114.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.117 0 178 292 365 443 293 95 280 225 373 909 664
2022/20235.150 641 704 254 655 313 385 164 266 866 141 456 305
2023/20242.205 124 248 121 172 151 299 172 179 91 187 199 262
2024/20255.472 325 876 480 416 834 294 580 204 105 262 169 927
2025/202611.743 761 921 1.105 1.047 1.388 684 1.028 350 2.530 1.044 461 424
2026/2027912 360 552 0 0 0 0 0 0 0 0 0 0
Totale 43.059